This occurred as the drug major Emcure Pharmaceuticals presented bioequivalence study report along with the Phase-III ...

Seattle biopharma company HDT Bio Corp has sued Indian generic drugmaker Emcure Pharmaceuticals Ltd in U.S. court for allegedly stealing RNA-delivery technology to use in its COVID-19 vaccine.

Emcure Pharmaceuticals IPO subscription opens with ₹582 crore raised from anchor investors. Price range set at ₹960-1,008 per share. IPO closes on July 5 with allocation percentages for ...

Emcure Pharmaceuticals Ltd reported a strong performance for the first quarter ended June 30, 2025, registering a 15.7 per ...

The latest announcement is out from Emcure Pharmaceuticals Limited ( (IN:EMCURE) ). Emcure Pharmaceuticals Limited announced the scheduling of its 44th Annual General Meeting (AGM) on August 28, 2025 ...

Emcure Pharmaceuticals IPO subscription status: The market as a whole was strong, and investors responded well to Emcure Pharmaceuticals' initial public offering (IPO) on the second bidding day ...

During the January-March period, Emcure Pharmaceuticals' revenue from operations stood at Rs 2,116 crore, up 19.5 per cent year-on-year from Rs 1,771 crore. PTI Updated: Thursday, May 22, 2025, 08 ...

Emcure also has operations in Canada, having acquired Ottawa-based International Pharmaceutical Generics and its marketing operation Marcan Pharmaceuticals in 2016.

Emcure Pharmaceuticals IPO GMP Read more: How much you can save from Uttar Pradesh's waiver of registration fee on hybrid cars Ahead of the listing, Emcure Pharma IPO GMP on July 9 is +352 which ...

Emcure Pharmaceuticals, a Pune-based company and a powerhouse in the pharmaceutical industry, has received approval from the market regulator SEBI to launch its much anticipated Initial Public ...

Emcure Pharmaceuticals has had its share of run-ins with the FDA in the past over the sterility of one of its Indian manufacturing plants. Now, it can notch one more black mark on its belt.